Cadila Healthcare’s API manufacturing facility at Dabhasa successfully completes USFDA inspection

Cadila Healthcare’s API manufacturing facility at Dabhasa successfully completes USFDA inspection

Cadila Healthcare Limited announced today that the USFDA inspected its Active Pharmaceutical Ingredients (API) manufacturing facility at Dabhasa, the group’s largest API manufacturing site, from 7th to 11th October 2019. This was a cGMP audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.